Identification of 1-and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling

被引:46
作者
Aranibar, Nelly [1 ]
Vassallo, Jeffrey D. [1 ]
Rathmacher, John [2 ]
Stryker, Steve [1 ]
Zhang, Yingru [1 ]
Dai, Jun [1 ]
Janovitz, Evan B. [1 ]
Robertson, Don [1 ]
Reily, Michael [1 ]
Lowe-Krentz, Linda [3 ]
Lehman-McKeeman, Lois [1 ]
机构
[1] Bristol Myers Squibb Co, Princeton, NJ 08540 USA
[2] Iowa State Univ, Ames, IA 50010 USA
[3] Lehigh Univ, Dept Biol, Bethlehem, PA 18015 USA
关键词
Metabolomics; Metabonomics; NMR; GC-MS; 1-Methylhistidine; 3-Methylhistidine; Muscle toxicity; Myopathy; Cerivastatin; Isoproterenol; GENE-EXPRESSION; PROTEIN-TURNOVER; URINARY CREATINE; RAT; CARNOSINE; DAMAGE; ANSERINE; TISSUES; BIOSYNTHESIS; SPECTROSCOPY;
D O I
10.1016/j.ab.2010.11.023
中图分类号
Q5 [生物化学];
学科分类号
070307 [化学生物学];
摘要
Nuclear magnetic resonance (NMR)-based metabolomic profiling identified urinary 1- and 3-methylhistidine (1- and 3-MH) as potential biomarkers of skeletal muscle toxicity in Sprague-Dawley rats following 7 and 14 daily doses of 0.5 or 1 mg/kg cerivastatin. These metabolites were highly correlated to sex-, dose- and time-dependent development of cerivastatin-induced myotoxicity. Subsequently, the distribution and concentration of 1- and 3-MH were quantified in 18 tissues by gas chromatography-mass spectrometry. The methylhistidine isomers were most abundant in skeletal muscle with no fiber or sex differences observed; however, 3-MH was also present in cardiac and smooth muscle. In a second study, rats receiving 14 daily doses of 1 mg/kg cerivastatin (a myotoxic dose) had 6- and 2-fold elevations in 1- and 3-MH in urine and had 11- and 3-fold increases in 1- and 3-MH in serum, respectively. Selectivity of these potential biomarkers was tested by dosing rats with the cardiotoxicant isoproterenol (0.5 mg/kg), and a 2-fold decrease in urinary 1- and 3-MH was observed and attributed to the anabolic effect on skeletal muscle. These findings indicate that 1 and 3-MH may be useful urine and serum biomarkers of drug-induced skeletal muscle toxicity and hypertrophy in the rat, and further investigation into their use and limitations is warranted. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:84 / 91
页数:8
相关论文
共 51 条
[1]
Abe H, 2000, BIOCHEMISTRY-MOSCOW+, V65, P757
[2]
Beta adrenoceptor agonists, clenbuterol, and isoproterenol retard denervation atrophy in rat gastrocnemius muscle: Use of 3-methylhistidine as a marker of myofibrillar degeneration [J].
Agrawal, S ;
Thakur, P ;
Katoch, SS .
JAPANESE JOURNAL OF PHYSIOLOGY, 2003, 53 (03) :229-237
[3]
Profiling histidine-containing dipeptides in rat tissues by liquid chromatography/electrospray ionization tandem mass spectrometry [J].
Aldini, G ;
Orioli, M ;
Carini, M ;
Facino, RM .
JOURNAL OF MASS SPECTROMETRY, 2004, 39 (12) :1417-1428
[4]
HINDLIMB MUSCLE FIBER POPULATIONS OF 5 MAMMALS [J].
ARIANO, MA ;
ARMSTRONG, RB ;
EDGERTON, VR .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1973, 21 (01) :51-55
[5]
3-METHYLHISTIDINE A COMPONENT OF ACTIN [J].
ASATOOR, AM ;
ARMSTRONG, MD .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1967, 26 (02) :168-+
[6]
BIOSYNTHESIS OF CARNOSINE AND RELATED PEPTIDES BY SKELETAL-MUSCLE CELLS IN PRIMARY CULTURE [J].
BAUER, K ;
SCHULZ, M .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 219 (1-2) :43-47
[7]
Bender HS., 2003, Duncan and Prasse's veterinary laboratory medicine - clinical pathology, V4th, P260
[8]
Strategic use of immunoprecipitation and LC/MS/MS for trace-level protein quantification: Myosin light chain 1, a biomarker of cardiac necrosis [J].
Berna, Michael J. ;
Zhen, Yuejun ;
Watson, David E. ;
Hale, John E. ;
Ackermann, Bradley L. .
ANALYTICAL CHEMISTRY, 2007, 79 (11) :4199-4205
[9]
BOHLMEYER TJ, 1994, RHEUM DIS CLIN N AM, V20, P845
[10]
Correlation analysis of gene expression and clinical chemistry to identify biomarkers of skeletal myopathy in mice treated with PPAR agonist GW610742X [J].
Casey, W. M. ;
Brodie, T. ;
Yoon, L. ;
Ni, H. ;
Jordan, H. L. ;
Cariello, N. F. .
BIOMARKERS, 2008, 13 (04) :364-376